Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aclaris Therapeutics, Inc.ACRS · Entity 5041 | Director · CEO | February 02, 2026 | February 06, 2026 |
| Aldeyra Therapeutics, Inc.ALDX · Entity 6839 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aclaris Therapeutics, Inc.
Report date February 02, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 274,800 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 274,800 · Balance 274,800 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2036-02-01 | Direct | 961,700 |
Reported balance
After 2026-02-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-02 · Grant · Acquired 961,700 · Balance 961,700 F3: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F3: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
Aldeyra Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08 | Direct | 70,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 70,000 · Balance 70,000 F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08 | Direct | 3,318 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 3,318 · Balance 3,318 F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2022 Filed Mar 3, 2022 23:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 18,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015794 · doc4.xml · derivative · entry 8 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,508 Underlying: Common Stock · 18,254 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F6 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F6 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 23:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 18,254 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-015794 · doc4.xml · nonDerivative · entry 3 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,372,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 18,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015794 · doc4.xml · derivative · entry 7 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,825 Underlying: Common Stock · 18,275 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F5 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 96,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015794 · doc4.xml · derivative · entry 6 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,150 Underlying: Common Stock · 96,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 96,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015794 · doc4.xml · derivative · entry 5 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock · 96,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 336,100 | $0.00 Strike: $14.94 | $0.00 |
DisclosureSEC source: 0001209191-22-015794 · doc4.xml · derivative · entry 4 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,100 Underlying: Common Stock · 336,100 shares Expires 2032-02-29 F2 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal annual installments beginning on March 1, 2023, subject to Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 18,275 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-015794 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,353,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 96,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-015794 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,335,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 3,595 | $12.66 | $45,513.42 |
DisclosureSEC source: 0001209191-22-008837 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,239,387 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on February 1, 2022 pursuant to preexisting sell-to-cover elections. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.6601 to $12.6610, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:43 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 10,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006826 · doc4.xml · derivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vested on February 1, 2022. F2 · derivative.expiration_date: The shares underlying these restricted stock units vested on February 1, 2022. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:43 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 10,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-006826 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,242,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 21:45 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 583 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0000899243-21-023009 · doc4.xml · derivative · entry 2 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 583 Underlying: Common Stock · 583 shares Expires 2031-06-07 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 21:45 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 13,534 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0000899243-21-023009 · doc4.xml · derivative · entry 1 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,534 Underlying: Common Stock · 13,534 shares Expires 2031-06-07 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 01:41 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 5,517 | $22.30 | $123,038.48 |
DisclosureSEC source: 0001209191-21-037473 · doc4.xml · nonDerivative · entry 3 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,232,182 F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.01 to $22.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 01:41 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 27,743 | $21.51 | $596,696.44 |
DisclosureSEC source: 0001209191-21-037473 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,237,699 F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.005 to $21.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 01:41 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 73,015 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-037473 · doc4.xml · derivative · entry 4 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 73,015 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 01:41 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 73,015 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-037473 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,265,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| April 22, 2021 Filed Apr 27, 2021 01:43 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 30,000 | $26.84 | $805,239.00 |
DisclosureSEC source: 0001209191-21-028451 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,192,427 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2021. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.51 to $27.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:32 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 18,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017519 · doc4.xml · derivative · entry 8 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,762 Underlying: Common Stock · 18,253 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F6 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F6 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:32 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 7,982 | $23.25 | $185,581.50 |
DisclosureSEC source: 0001209191-21-017519 · doc4.xml · nonDerivative · entry 4 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,222,427 F2 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:32 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 18,253 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-017519 · doc4.xml · nonDerivative · entry 3 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,230,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:32 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 96,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017519 · doc4.xml · derivative · entry 7 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,300 Underlying: Common Stock · 96,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F5 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:32 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 73,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017519 · doc4.xml · derivative · entry 6 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,100 Underlying: Common Stock · 73,100 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:32 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 255,800 | $0.00 Strike: $24.06 | $0.00 |
DisclosureSEC source: 0001209191-21-017519 · doc4.xml · derivative · entry 5 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,800 Underlying: Common Stock · 255,800 shares Expires 2031-02-28 F3 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of the grant date, subject to Reporting Person's continuous service through each such date. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:32 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 39,792 | $24.06 | $957,395.52 |
DisclosureSEC source: 0001209191-21-017519 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,212,156 F2 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:32 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 96,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-017519 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,251,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:23 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 10,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007368 · doc4.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,800 Underlying: Common Stock · 10,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:23 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 3,316 | $21.35 | $70,796.60 |
DisclosureSEC source: 0001209191-21-007368 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,155,798 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:23 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 10,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-007368 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,159,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 22:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 3,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064127 · doc4.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,034 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On December 15, 2016, the reporting person was granted 24,266 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vested in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: On December 15, 2016, the reporting person was granted 24,266 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vested in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 22:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 871 | $4.59 | $3,997.89 |
DisclosureSEC source: 0001209191-20-064127 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,148,314 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 22:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 3,034 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-064127 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,149,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:23 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 83,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-049398 · doc4.xml · derivative · entry 4 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,092 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest immediately. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest immediately. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:23 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 83,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-049398 · doc4.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,092 Underlying: Common Stock · 83,092 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest immediately. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest immediately. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:23 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 23,872 | $2.33 | $55,621.76 |
DisclosureSEC source: 0001209191-20-049398 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,146,151 F2 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:23 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 83,092 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-049398 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,170,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 21:46 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 1,541 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0000899243-20-016180 · doc4.xml · derivative · entry 2 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,541 Underlying: Common Stock · 1,541 shares Expires 2030-06-08 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 21:46 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 26,503 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0000899243-20-016180 · doc4.xml · derivative · entry 1 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,503 Underlying: Common Stock · 26,503 shares Expires 2030-06-08 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:47 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 73,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034076 · doc4.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,015 Underlying: Common Stock · 73,014 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:47 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 20,976 | $1.32 | $27,688.32 |
DisclosureSEC source: 0001209191-20-034076 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,086,931 F2 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:47 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 73,014 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-034076 · doc4.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,107,907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 52,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016095 · doc4.xml · derivative · entry 10 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F7 · derivative.exercise_date: The shares underlying these restricted stock units vest immediately. F7 · derivative.expiration_date: The shares underlying these restricted stock units vest immediately. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 52,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016095 · doc4.xml · derivative · entry 9 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,564 Underlying: Common Stock · 52,564 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F7 · derivative.exercise_date: The shares underlying these restricted stock units vest immediately. F7 · derivative.expiration_date: The shares underlying these restricted stock units vest immediately. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 73,015 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016095 · doc4.xml · derivative · entry 8 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,015 Underlying: Common Stock · 73,015 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F6 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F6 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 146,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016095 · doc4.xml · derivative · entry 7 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,029 Underlying: Common Stock · 146,029 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F5 · derivative.expiration_date: The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 255,552 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001209191-20-016095 · doc4.xml · derivative · entry 6 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,552 Underlying: Common Stock · 255,552 shares Expires 2030-03-01 F4 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of the grant date, subject to Reporting Person's continuous service through each such date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 96,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016095 · doc4.xml · derivative · entry 5 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,450 Underlying: Common Stock · 96,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 15,101 | $1.26 | $19,027.26 |
DisclosureSEC source: 0001209191-20-016095 · doc4.xml · nonDerivative · entry 4 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,034,893 F2 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 52,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-016095 · doc4.xml · nonDerivative · entry 3 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,049,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 27,623 | $1.26 | $34,804.98 |
DisclosureSEC source: 0001209191-20-016095 · doc4.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 997,430 F2 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.